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ABSTRACT
Objective: The objective of this systematic review is to determine whether or not “Does fish oil
supplementation (omega-3 PUFA) cause mood improvement in adults with depression?”
Study Design: Review of all English language primary double blind randomized controlled trial
studies from 1997-2010
Data Sources: Randomized, controlled, double-blind clinical trials comparing fish oil
supplementation to placebo were found using OVID, PubMed, Medline and Cochrane databases
Outcomes Measured: Each of the three trials compared mood improvement in depressed
patients using depression scales, such as the Hamilton Rating Scale for Depression and the Beck
Depression Inventory, and subjective ratings, such as aches/pains, energy, fatigue, sleep and
appetite. Study participants were evaluated at baseline and subsequently evaluated at 2-3 week
increments for 8, 12 or 16 weeks.
Results: Three double-blind randomized controlled trials were included in this review. The
study done by Kuan-Pin used 440mg EPA and 220mg DHA and indicated a significant reduction
in HRSD score for the omega-3 PUFA group in comparison to the placebo group beginning at
the fourth week of the trial. The remaining two studies, by Grenyer and Silvers, used 0.6g EPA
and 2.2 and 2.4g DHA, respectively, and did not find any significant difference in mood
improvement between participants taking omega-3 PUFA and participants in the placebo group.
Participants in each of the three studies reported minor adverse effects however none
encountered any major adverse effects caused by the therapy.
Conclusions: The results of the Kuan-Pin trial using 440mg EPA and 220mg DHA showed that
omega-3 PUFA may be effective in improving mood in adults with depression based on the
Hamilton Rating Scale for Depression. The Grenyer and Silvers study using 0.6gEPA and 2.2
and 2.4g DHA, respectively, did not show a significant improvement in mood for adult
depression patients using the therapy.
Key Words: Fish oil, Omega-3 fatty acids, Depression
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INTRODUCTION
Depression is defined as a depressed mood that is present daily and persists for at least a
period of two weeks. Frequent episode characterizations of depression include anhedonia,
apathy, sadness or irritability. It is one of the most common mental health problems experienced
by individuals in the United States marked by a lifetime prevalence of 16.2%. Onset occurs
anywhere from childhood to late life; however, the mean age of onset is the late 20s, with the
incidence rate for adult women twice as great in comparison to men. The effect of depression on
an individual not only causes emotional instability, but also physical signs and symptoms.
Patients affected by depression often do not seek medical care for the illness, which
accounts for an extensive number of undiagnosed cases. While the exact number of annual
healthcare visits for depression is unknown, data does show that depressed individuals most
often present to primary care physicians and emergency rooms. The estimated cost of depression
for the US economy is $43 billion annually. These expenses are related to care, absenteeism,
reduced productivity on the job, premature death and suicide. The total amount of US healthcare
expenses for the treatment of depression amounts to $12 billion per year.
The exact etiology of depression remains unknown; yet, there are a number of factors that
are theorized to increase a person’s risk for the disease: genetics, neurotransmitter alterations,
neuroendocrine dysregulations, negative life events, and stressful environments. A patient
presenting with depression admits to depressed mood and anhedonia daily for at least two weeks,
as well as five or more of the following clinical features: sleep (insomnia or hypersomnia),
decreased interest, guilt and worthlessness, fatigue, impaired concentration, decreased or
increased appetite, psychomotor retardation or agitation, suicide, or somatic complaints
(headache, backache, GI complaints, dizziness, lethargy). The mainstays of treatment for
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depression include psychotherapy and pharmacotherapy, with best results stemming from the
combination of the two. OTC remedies such as St. John’s Wort are also used as adjuvant
therapies for depressed patients. Persistent cases of depressions despite the use of
pharmacological and behavioral therapies may benefit from surgical interventions such as
electroconvulsive therapy or vagus nerve stimulation. The forementioned depression treatment
options require extended periods of time before effective and are often associated with negative
side effects. In lieu of this, fish oil supplementation may provide significant improvement in
mood for depressed adults over other products and therapies, giving healthcare providers the
option of introducing omega-3 PUFA supplements into the course treatment of individuals
affected by major depressive disorder.
OBJECTIVE
The objective of this systematic review is to determine whether or not “Does fish oil
supplementation (omega-3 PUFA) cause mood improvement in adults with depression?”
METHODS
All three studies selected for this review met the following criteria. The population
included adults age 18 and older with a clinical diagnosis of depression. The intervention used
in the studies was fish oil (omega-3 PUFA) supplementation in the following three doses: 440mg
EPA and 220mg DHA (Kuan-Pin et al), 0.6g EPA and 2.2g DHA (Grenyer et al) and 0.6g EPA
and 2.4g DHA (Silvers et al). Only those articles that compared the treatment groups receiving
omega-3 PUFA supplementation compared to a placebo group were considered. Outcomes were
based on mood improvement in depressed patients using depression scales and subjective
ratings, which qualifies as patient oriented evidence that matters (POEM). Three double-blind,
randomized, placebo-controlled clinical trials were identified and included in this review.
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The key words fish oil, omega-3 fatty acids, and depression were used in combination to
search literature for English articles, of which all resulting articles were published in peerreviewed journals. A detailed literature search and selection of studies for this review was
completed by the author using OVID, Medline, PubMed and Cochrane databases. Inclusion
studies were those that were randomized, controlled, prospective and based on patients outcomes
(POEMS) dated after 1996. Studies excluded from this review were articles that included
patients less than 18 years of age. Statistics utilized in the studies include p-values, NNH, chisquare, t-test, and Intention to Treat (ITT).
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Table 1: Demographics and characteristics included for analysis of fish oil supplementation in
the treatment of depression

Study

Type

#
Pts
83

Age
(yrs)
1870

Inclusion
Criteria
Pts with a
primary
diagnosis of
major
depression
based on
DSM-IV
criteria and
HDRS score
>16

Grenyer,
2007 (1)

Double
-blind
RCT

Silvers,
2005 (2)

Double
-blind
RCT

77

1865

Healthy
males and
females
between the
ages of 18-65
with a
current
diagnosis of
depression ad
current
medication
use >2
months

KuanPin,
2003 (3)

Double
-blind
RCT

32

1860

Exclusion
Criteria
Pts with a serious
medical condition,
objection to
venipuncture, comorbid substance
abuse, psychotic,
bipolar or eating
disorder, or OCD

Pts with a co-existing
psychiatric disorder,
post-menopausal or
irregular menstruation
cycle (females), blood
clotting disorder, use
of anticoagulants,
unstable medical
condition, seafood
allergies, objections to
taking fish oil or olive
oil-based products, or
objections to
venipuncture
Healthy pts
Pts with co-morbid
from 18-60yo Axis I or II psychiatric
with a major disorder, change in
depressive
medications or
diagnosis
psychotherapy 4
based upon
weeks prior to
DSM-IV
enrollment,
criteria and
incompetent or unable
>18 on
to understand study
Hamilton
rules, >20% decreased
Rating Scale in HRSD score during
for
placebo-lead-in phase
Depression

W/D

Interventions

23

Eight 1g soft
gelatin
capsule of
pacific tuna
oil (provided
3g of omega3 PUFA) per
day VS.
Eight 1g soft
gel capsules
of olive oil
per day for
16 weeks
8g soft gel
capsule of
DHA
enriched tuna
fish oil per
day VS. 8g
soft gel
capsule of
olive oil per
day for 12
weeks

18

10

Five gelatin
capsules
containing
omega-3
fatty acids
BID VS. five
gelatin
capsules
containing
olive oil
ethyl esters
BID for 8
weeks
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OUTCOME MEASURED
Each of the three studies measured participants’ outcome of mood improvement based on
depression scales and subjective ratings. Depression scales included the 21-item Hamilton
Depression Rating Scale (Kuan-Pin et al, Silvers et al and Grenyer et al) and the Beck
Depression Inventory (Silvers et al and Grenyer et al). HDRS is a 21-question survey performed
by a healthcare professional that assesses a patient’s severity of depression. Assessment
questions include the following topics: depressed mood, feelings of guilt, suicide, insomnia,
work and activities, psychomotor retardation, agitation, psychological agitation, anxiety, somatic
symptoms, genital symptoms, hypochondriasis, weight loss, insight, diurnal variation,
depersonalization, paranoid symptoms and obsessive and compulsive symptoms. Scores between
7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and
scores over 24 indicate severe depression. BDI is a 21-item self-report survey that also assesses
depression severity. Each answer is scored on a scale from 0-3. Score breakdown is as follows:
0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; and 29-63:
severe depression. As the same with HDRS, higher total scores for BDI indicates more severe
depressive symptoms. Subjective ratings took into account participants’ degree of aches/pains,
energy, fatigue, sleep, and appetite.
The Global Assessment of Functioning (GAF) was used by Grenyer as a secondary
means of measuring patient outcomes. GAF is a numeric scale (0-100) that is used by therapists
and physicians to subjectively assess adult function in social, occupational and psychological
aspects of life.
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RESULTS
The three randomized controlled trials presented in this review are double-blind,
prospective clinical trials that provided continuous data to assess the outcome of mood
improvement in adults with a clinical diagnosis of depression. Treatment results were based on
changes in HRDS scores (Kuan-Pin and Silvers) or BDI scores (Silvers and Grenyer) as shown
in Table 2. Analysis of harm for all three studies was done by converting the continuous data to
dichotomous data and presented as NNH (number needed to harm) analysis (Table 3).
The Kuan-Pin study, which originally enrolled 32 participants, completed the eight-week
trial with a total of 22 participants ranging from 18-60 years old. At baseline, the omega-3
PUFA group had a mean HRSD score of 22.5, while the mean score for the placebo group was
22.1. The experimental group received a total of 4,400mg EPA and 2,200mg DHA per day.
Participants were assessed at weeks 0, 2, 4, 6 and 8. At week 8, participants in the omega-3
PUFA group had a mean HRSD score of 8.9, while participants in the placebo group had a mean
score of 15.7. According to the study, the percent reduction in HRSD scores for the omega-3
PUFA group was significantly greater than that of the placebo group (p = 0.001).
Silvers et al randomly assigned 40 participants to receive fish oil and 37 participants to
receive placebo. At completion of the 12-week study, the trial participant composition included
24 fish oil participants and 21 placebo participants, all of which fell into the age group of 18-65.
Each participant of the fish oil group received a total of 0.6g EPA and 2.4g DHA per day.
Assessment of mood took place at baseline, and then at weeks 2, 4, 8 and 12 using the selfadministered HDRS and Beck Depression Inventory (BDI). Mean baseline HDRS scores for the
fish oil group and placebo group were 12.4 and 11.5, respectively. The fish oil group and
placebo group mean BDI scores at baseline were 23.3 and 21.9, respectively. At week 12, the
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placebo group and fish oil group had a mean change in HDRS score of 0.6 (p = 0.6) and 0.3 (p =
0.8), respectively. Mean changes in BDI scores were 1.5 (p = 1.5) and 0.3 (p = 1.5) for the
placebo group and fish oil group, respectively. According to this data, there is no evidence that
fish oil improved mood for enrolled participants.
Grenyer et al randomized 83 participants aged 18-70 to fish oil or placebo at the start of
the study, with 60 participants completing the 16-week trial (28 placebo and 32 fish oil). Each
participant of the fish oil group received 2.2g DHA and 0.6g EPA per day. Mood assessments
were completed at week 0, 3, 6, 9, 12 and 16 using the HDRS and BDI. According to Grenyer,
there was no significant interaction effect between time and group according to both the HDRS
and BDI with p-values equaling .844 and .424, respectively. Mean BDI scores for the placebo
group and fish oil group at baseline were 28 and 25, respectively. Upon completion of the trial,
mean BDI scores for placebo and fish oil participants were 17.5 and 12, respectively. The overall
Global Assessment of Functioning (GAF) scores did improve for both groups over time; baseline
GAF scores averaged at 51 and improved to an average of 68 at week 16. Despite this, the
scores were not found to be significant (p = .399). In terms of subjective ratings, Grenyer noted
no differences in aches/pains, energy, fatigue, sleep or appetite between groups over the course
of the 16 weeks.
Table 2: Efficacy of fish oil on mood improvement for depressed adults
Baseline
HDRS
Fish oil
Group

Post-tx
HDRS
Fish oil
Group

Baseline
HDRS
Placebo
Group

Post-tx
HDRS
Placebo
Group

Baseline
BDI
Fish oil
Group

Post-tx
BDI
Fish oil
Group

Baseline
BDI
Placebo
Group

Post-tx
BDI
Placebo
Group

KuanPin

22.5

8.9

22.1

15.7

X

X

X

X

Silvers

11.5

11.8

12.4

13.0

21.9

22.2

23.3

24.8

Grenyer

23.5

10.7

Unknown

Unknown

25

12

28

17.5

Study
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All three studies presented data in the form of continuous data. In order to analyze the
harm for each trial, the data was converted into dichotomous data and analyzed as NNH.
Participants that experienced no adverse effects to mild adverse symptoms were considered to
have insignificant changes, while participants with marked adverse effects were considered
significant changes. The CER (control event rate) was determined by the number of patients that
experienced adverse symptoms as part of the placebo group. The EER (experimental event rate)
was based upon the percentage of patients in the fish oil group that experienced significant
negative effects. Using this data, RRI (relative risk increase) and ARI (absolute risk increase)
was calculated. NNH (number needed to harm) is the number of patients that need to be treated
with fish oil before a detrimental event occurs.
Table 3: Analysis of harm based on participants treated with fish oil vs. placebo for depression
Study
Kuan-Pin

# participants
32

CER
10%`

EER
17%

RRI
70%

ARI
7%

NNH
14

Silvers

77

37%

35%

5%

-2%

50

Grenyer

83

0%

78

0

78

1

The most common side effects noted by Silvers et al were gastrointestinal disturbance
and/or reflux, which were experienced by both the experimental and control groups. The only
adverse effect experienced by participants of the Grenyer trial was a change in stools. This was
experienced equally among the fish oil and placebo groups. Kuan-Pin et al noted that among the
fish oil participants, one experienced mild excitement and another had mild diarrhea. One
participant in the placebo group experienced insomnia for a two-week period during the course
of study. Among all three studies presented, none of the participants experienced any major
adverse effects related to the therapies provided throughout the trial.
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Compliance issues were not a major factor for any of the three studies. Grenyer et al lost
23% of participants originally enrolled in the study due to violation of the trial protocol.
Reasons included time/commitment, moving out of area, hospitalizations and time constraints.
Grenyer noted that analyses of completers versus drop outs found no significant differences in
measures at any point in time. According to Silvers et al, 63% of participants in the fish oil
group and 63% of participants in the placebo group admitted to non-compliance with doses.
Reasons included unable to take capsules as requested, capsules too large to swallow, GI
disturbances, capsules showed no improvements, or stopped capsules because improvements
were experienced. In lieu of this, there was no evidence that non-compliance was related to the
assigned therapy (p = 0.976). Kuan-Pin et al lost six participants during the eight-week course of
the study (2 fish oil and 4 placebo). Reasons were due to lost in follow-up or non-compliance.
DISCUSSION
Omega-3 fatty acids are a family of unsaturated fatty acids with a common carbon-carbon
double bond located at the n-3 position. Two of the most common types are eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), both of which are polyunsaturated fatty acids.
Since the body is unable to synthesize omega-3 fatty acids on its own, individuals must obtain
sources from food or supplementation. It is widely known that omega-3 fatty acids are an
essential component for normal growth and development, but recent studies have since increased
our knowledge surrounding the associated health benefits. Most notably, omega-3 fatty acids are
used to treat patients with hypertriglyceridemia, coronary artery disease, and hypertension. The
American Heart Association recommends that patients with coronary artery disease consume 1g
of fish oil per day, preferably by eating fish. Lovanza, a new drug on the market indicated for
patients with severe hypertriglyceridemia, is composed of a combination of ethyl esters of
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omega-3 fatty acids, principally EPA and DHA. For individuals that do not meet criteria for
prescription omega-3 fatty acids, supplements are widely available OTC at pharmacies
throughout the US. Other conditions known to benefit from fish oil ingestion include cancer
(particularly breast, colon and prostate cancer), Alzheimer’s and Parkinson’s disease. While
negative symptoms associated with fish oil supplementation is rare, one of the major adverse
effects is prolonged bleeding times; doses of omega-3 fatty acids that exceed 3 grams per day
may increase a patient’s risk of bleeding and could put a person at risk for hemorrhagic stroke.
Omega-3 fatty acids also have been shown to increase levels of LDLs, which should be used
cautiously in patients with a history of hyperlipidemia.
The three studies presented in this review were all faced with certain limitations. 27% of
participants in the Grenyer study, 23% of participants in the Silvers study, and 31% of
participants in the Kuan-Pin study withdrew from the trial throughout the course of study. The
potential outcomes associated with those participants were not analyzed as part of each study,
but could have significantly impacted results if experimental participant HRDS or BDI scores
were statistically significant in comparison to placebo. Silvers et al measured patient outcomes
based on self-administered ratings only. In comparison, Kuan-Pin et al and Grenyer et al used
self-administered ratings as well as healthcare professional survey scores to measures the
outcomes of mood improvement for enrolled participants. Allowing individuals to assess their
own mood improvement leaves room for dishonesty, resulting in unreliable data. In all three
studies, participants often correctly guessed to which group they were randomized based upon
the fishy aftertaste of the fish oil capsules. Future studies would benefit from concealing the fish
oil taste by alternate means in order to devise a completely blinded trial.
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CONCLUSIONS
The three studies reviewed for this paper provided each of their respective experimental
fish oil groups with a certain dosage of EPA and DHA, both of which belong to the family of
omega-3 PUFA. Two of the three studies determined that daily fish oil intake had no impact on
mood improvement in adult patients with a clinical diagnosis of depression. The remaining
study noted that while fish oil participants did in fact see an improvement in mood over the
course of the trial, there is need for further studies in order to truly determine the effectiveness of
omega-3 PUFA supplementation. Taking all results into consideration, it is decided that adult
depression patients cannot use fish oil supplements as a means to improve mood. Future studies
may wish to experiment with other types of omega-3 PUFA, instead of relying solely on EPA
and DHA.
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